Pharmaceuticals, Biotechnology and Life Sciences
− Enrollment Completed in Phase 3 INVIGORATE Trial, with Top-Line Results Expected in the First Half of 2021
− Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Trials Expected in the Second Half of 2021
− Projected Cash Runway Through 202…
– Significant progress achieved across pipeline of Bicycle® Toxin Conjugates (BTCs™) and tumor targeted immune cell agonists (TICAs™)
– Cash of $136.0 million at December 31, 2020 expected to provide financial runway through multiple clinical milesto…
CHICAGO–(BUSINESS WIRE)–Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today a…
Dramatically lower COVID-19 disease incidence rates observed in individuals fully vaccinated with the Pfizer-BioNTech vaccine, based on real-world data gathered by the Israel Ministry of Health
Data suggest Pfizer-BioNTech vaccine prevents asympt…
CAMBRIDGE, Mass. & LONDON–(BUSINESS WIRE)–Centessa Pharmaceuticals (“Centessa”), a pharmaceutical company consisting of 10 subsidiary companies advancing a portfolio of high conviction programs with strong biological validation, today announced key a…
CAMBRIDGE, Mass. & LONDON–(BUSINESS WIRE)–Centessa Pharmaceuticals (“Centessa”), a pharmaceutical company consisting of 10 subsidiary companies advancing a portfolio of high conviction programs with strong biological validation, today announced key a…
– Recent KVD900 Phase 2 Clinical Trial Results Statistically and Clinically Significant –
– IND Submitted for Oral Prophylactic HAE Treatment Candidate KVD824; Phase 2 Expected to Initiate in Q2 2021 –
– Following Upsized Public Offering, Funded to …
– Recent KVD900 Phase 2 Clinical Trial Results Statistically and Clinically Significant –
– IND Submitted for Oral Prophylactic HAE Treatment Candidate KVD824; Phase 2 Expected to Initiate in Q2 2021 –
– Following Upsized Public Offering, Funded to …
– Recent KVD900 Phase 2 Clinical Trial Results Statistically and Clinically Significant –
– IND Submitted for Oral Prophylactic HAE Treatment Candidate KVD824; Phase 2 Expected to Initiate in Q2 2021 –
– Following Upsized Public Offering, Funded to …
– Recent KVD900 Phase 2 Clinical Trial Results Statistically and Clinically Significant –
– IND Submitted for Oral Prophylactic HAE Treatment Candidate KVD824; Phase 2 Expected to Initiate in Q2 2021 –
– Following Upsized Public Offering, Funded to …